返回 Agenda
Session 9: Selecting COA Endpoints and Analyzing COA Data in Rare Disease - Dealing with Small Sample Sizes and Heterogeneity
Session Chair(s)
Emuella Flood
Director, Patient-Reported Outcomes
AstraZeneca, United States
Rare disease populations are typically small and heterogeneous, and often involve different subtypes, such as specific gene mutation subgroups, further reducing sample sizes. Specific COA-related challenges related to small sample sizes and heterogeneity of rare diseases include the selection and validation of COA measures and analyzing and interpreting the COA data to support treatment benefit. This session will identify the challenges of selecting COA endpoints and analyzing COA data in rare disease populations, including in evaluating psychometric properties of COA instruments. Potential Solutions will be offered, illustrated though case examples. The regulatory perspective on addressing these challenges will also be presented.
Learning Objective :
At the conclusion of this session, participants should be able to:- Identify the challenges of COA endpoint selection and analysis in rare disease populations and potential solutions, such as the use of RWE and composite endpoints
- Employ strategies to perform psychometric validation in small, heterogeneous samples
- Discuss the regulatory perspective on endpoint selection and analysis in rare disease
Speaker(s)
Selecting COA Endpoints and Analyzing COA Data in Rare Disease-Dealing with Small Sample Sizes and Heterogeneity
Laura Lee Johnson, PhD
FDA, United States
Director, Division of Biometrics III, Office of Biostatistics, OTS, CDER
Selection and Development of Patient-focused COAs for Rare Disease Clinical Trials
Linda Nelsen, MHS
GlaxoSmithKline, United States
Senior Director and Head, Oncology Patient-Centered Outcomes
Selecting COA Endpoints and Analyzing COA Data in Rare Disease-Dealing with Small Sample Sizes and Heterogeneity
Jeffrey Palmer
Pfizer Inc, United States
Senior Director, Biostatistics
Psychometric Evaluation with Small Samples
R.J. Wirth, PhD
Vector Psychometric Group, LLC, United States
CEO